Erforschung von KI-gestütztem Arzneimitteldesign, computergestützter Pharmakologie und programmierbarer Biologie.
Generative Modelle, AlphaFold und maschinelles Lernen beschleunigen molekulare Entdeckungen.
FEP, Molekulardynamik, Quantencomputing und Kryo-EM bei der Leitstrukturoptimierung.
PROTACs, programmierbare Proteine, Prodrugs und ADCs der nächsten Generation.
FDA-EMA-Rahmen, Marktanalyse und Ökonomie der KI-Arzneimittelforschung.
A comprehensive analysis of how generative AI models are transforming de novo molecular design, with the latest methods, tools, and clinical implications.
How DeepMind's AlphaFold 3 is revolutionizing structure-based drug design through protein-ligand complex prediction.
Exploring how AI platforms like PandaOmics identify novel drug targets and accelerate their journey to clinical trials.
A comprehensive guide to ML-based ADMET prediction methods, tools, and their role in reducing late-stage drug failures.
A detailed case study of rentosertib (INS018_055), the first AI-designed drug to reach Phase III clinical trials.
An in-depth analysis of FEP methods for predicting binding free energies and their transformative role in lead optimization.